Mårten Falkenberg/ Vascular News
Aug 31, 2025, 07:12
Late-Breaking SWEDEPAD Trial Finds No Benefit of Drug-Coated Balloons and Stents, Raises Safety Concerns
Vascular News shared an important post on LinkedIn:
“BREAKING NEWS: Drug-coated balloons and stents were not associated with reduced risk of amputation or improved quality of life compared with uncoated devices in the SWEDEPAD 1 and 2 trials. In addition, higher five-year mortality with drug-coated devices in patients with intermittent claudication was noted, leading researchers to stress that the safety of paclitaxel-coated devices is an “ongoing discussion”.
These late-breaking findings were presented today at the European Society of Cardiology (ESC) 2025 congress (29 August–1 September, Madrid, Spain) and simultaneously published in The Lancet Group.”
Read more here.
Stay updated with Hemostasis Today.
-
Jul 23, 2026, 15:58Mel Snyder: Beyond Sickle Cell Disease to the Future of Pediatric Genetics
-
Jul 23, 2026, 15:43Lorna Knight: The Next Frontier in Sickle Cell Disease Is Access
-
Jul 23, 2026, 15:29Ben Kleinstiver: Overcoming a Major Barrier to Scalable Gene Editing
-
Jul 23, 2026, 15:28Modernizing DIC Diagnosis in Cirrhosis: Building an International Registry for Precision Hemostasi
-
Jul 23, 2026, 14:32Saneha Anjum Shaikh: Why Antibody Screening Must Be Standard Practice in Modern Blood Banking
-
Jul 23, 2026, 14:00Ron Vezina: Canadian Blood Services Issues Urgent Donation Appeal
-
Jul 23, 2026, 13:46Sebastian Szmit: Understanding Troponins in Modern Cardio-Oncology
-
Jul 23, 2026, 13:41Colleen Grady: Why Normal Hemoglobin Does Not Exclude Iron Deficiency
-
Jul 23, 2026, 13:22Jacob Kelly: AHA Review Highlights Coffee’s Cardiovascular Benefits